107 related articles for article (PubMed ID: 23562091)
1. Targeting innate immunity in type 1 diabetes: strike one.
Bonifacio E
Lancet; 2013 Jun; 381(9881):1880-1. PubMed ID: 23562091
[No Abstract] [Full Text] [Related]
2. Therapy: Immunotherapy for T1DM--targeting innate immunity.
Wong FS; Wen L
Nat Rev Endocrinol; 2013 Jul; 9(7):384-5. PubMed ID: 23732280
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness of interleukin-1 inhibiton for mevalonate kinase deficiency].
Horneff G
Z Rheumatol; 2014 Jun; 73(5):398. PubMed ID: 25057522
[No Abstract] [Full Text] [Related]
4. New therapies for diabetes management.
Garg SK
Diabetes Technol Ther; 2013 Feb; 15 Suppl 1():S126-35. PubMed ID: 23441701
[No Abstract] [Full Text] [Related]
5. The anti-interleukin-1 in type 1 diabetes action trial--background and rationale.
Pickersgill LM; Mandrup-Poulsen TR
Diabetes Metab Res Rev; 2009 May; 25(4):321-4. PubMed ID: 19405081
[TBL] [Abstract][Full Text] [Related]
6. [2/2 The other biotherapies].
Fournel C; Medjoub M; Limat S; Woronoff-Lemsi MC
Soins; 2007 Nov; (720):59-61. PubMed ID: 18376755
[No Abstract] [Full Text] [Related]
7. Prolactin: An Effective Partner for Anti-CD3 in Treating Type 1 Diabetes.
Xiao X
Endocrinology; 2016 Jan; 157(1):39-41. PubMed ID: 26717470
[No Abstract] [Full Text] [Related]
8. [Treatment of diabetes mellitus with biologic therapeutics].
Larsen CM; Mandrup-Poulsen T
Ugeskr Laeger; 2008 Jun; 170(24):2134-7. PubMed ID: 18565296
[TBL] [Abstract][Full Text] [Related]
9. Rituximab, B-lymphocyte depletion, and beta-cell function.
Nagafuchi S; Katsuta H; Anzai K
N Engl J Med; 2010 Feb; 362(8):761; author reply 761. PubMed ID: 20181981
[No Abstract] [Full Text] [Related]
10. Can we change the course of beta-cell destruction in type 1 diabetes?
Gale EA
N Engl J Med; 2002 May; 346(22):1740-2. PubMed ID: 12037155
[No Abstract] [Full Text] [Related]
11. [Remission--therapy goal in rheumatoid arthritis].
Z Rheumatol; 2007 Feb; 66(1):2 p following 87. PubMed ID: 17896425
[No Abstract] [Full Text] [Related]
12. Anti-CD3 antibodies for type 1 diabetes: beyond expectations.
Bach JF
Lancet; 2011 Aug; 378(9790):459-60. PubMed ID: 21719098
[No Abstract] [Full Text] [Related]
13. Schnitzler syndrome: treatment failure to rituximab but response to anakinra.
Eiling E; Möller M; Kreiselmaier I; Brasch J; Schwarz T
J Am Acad Dermatol; 2007 Aug; 57(2):361-4. PubMed ID: 17467852
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and omalizumab in severe, refractory insulin allergy.
Yong PF; Malik R; Arif S; Peakman M; Amiel S; Ibrahim MA; Gough A
N Engl J Med; 2009 Mar; 360(10):1045-7. PubMed ID: 19264698
[No Abstract] [Full Text] [Related]
15. [Biological treatment options for Graves' ophthalmopathy].
El Fassi D; Nielsen CH; Hegedüs L
Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and immune thrombocytopenic purpura: a new association with good response to anti-CD20 therapy.
von Laer Tschudin L; Schwitzgebel VM; von Scheven-Gête A; Blouin JL; Hofer M; Hauschild M; Ansari M; Stoppa-Vaucher S; Phan-Hug F
Pediatr Diabetes; 2015 Mar; 16(2):138-45. PubMed ID: 24552605
[TBL] [Abstract][Full Text] [Related]
17. Type 1 diabetes.
Burn P
Nat Rev Drug Discov; 2010 Mar; 9(3):187-8. PubMed ID: 20190784
[No Abstract] [Full Text] [Related]
18. Type 1 diabetes--does suppressing T cells increase insulin?
Lernmark A
N Engl J Med; 2005 Jun; 352(25):2642-4. PubMed ID: 15972873
[No Abstract] [Full Text] [Related]
19. Immunotherapies in diabetes mellitus type 1.
Gupta S
Med Clin North Am; 2012 May; 96(3):621-34, xi. PubMed ID: 22703858
[TBL] [Abstract][Full Text] [Related]
20. The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.
Chatenoud L
Handb Exp Pharmacol; 2008; (181):221-36. PubMed ID: 18071948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
